Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Sai Life Sciences Limited

SAILIFE · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,557.50

+₹61.80 (+4.13%)(1D)

₹783.8552 Week Range₹1,697.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

62/100

Valuation

0/100

Quality

69/100

Growth

86/100

Health

80/100

Momentum

91/100

Valuation
0
Quality
69
Growth
86
Health
80
Momentum
91

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Sai Life Sciences Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,557.5

Market cap

₹33,012 Cr

P/E ratio

90.61

P/B ratio

13.29

Dividend yield

Not available

ROE

Not available

RSI 14

62.91

1Y return

Not available

Sai Life Sciences Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Sai Life Sciences Limited (SAILIFE) stock page cover?

Sai Life Sciences Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SAILIFE?

Sai Life Sciences Limited is currently shown with a delayed price near ₹1,557.5, P/E 90.61.

Does the SAILIFE page provide investment advice?

No. The SAILIFE page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

LALPATHLAB

Dr. Lal Path Labs Ltd. · Healthcare

SYNGENE

Syngene International Limited · Healthcare

VIJAYA

Vijaya Diagnostic Centre Limited · Healthcare

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Master AI-assisted stock research on Indian equities. Learn how to construct grounded financial queries, audit concall guidance, verify filing citations, and avoid ungrounded AI hallucinations.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

The company serves multiple therapeutic segments including Anti Histamine, Cardiovascular, CNS, Dermatology, Genetic Disorders, Immunology, Infectious Diseases, Metabolic Disorders, Oncology, and Others. Revenue growth is presented across FY22 to FY26, with a customer split showing significant contributions from Pharma and Biotech.

Diagnostics & ResearchFounded:1999CEO/MD:Krishna Kanumuri

Business profile as of 2026-08-25

Revenue growth: +29.4%FY26 growth
PAT growth: +105.1%FY26 growth
CFO / PAT: 1.46×FY26

What Looks Strong

IPOShares trade +94.4% above its first traded close of ₹764.65.
Cash FlowOperating cash flow was 1.46× total net profit in FY26.
TrendPrice momentum is strong, with the stock trading comfortably above its 200-day trend.

What to Watch

ValuationThe shares trade at 86× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.

Reports a single operating segment in its results filings.

FY26 (consolidated): revenue ₹2,192 cr, up 29% from ₹1,695 cr in FY25; net profit ₹349 cr, up 105% from ₹170 cr in FY25.
FY26 (consolidated): operating cash flow ₹509 cr (1.5× net profit); debt/equity 0.04×.
Latest quarter to Jun 2026 (consolidated): revenue ₹554 cr (up 12% year on year); net profit ₹73.3 cr.